Brian Goff
Chief Executive Officer, Director at Agios Pharmaceuticals, Inc. (AGIO)
Brian Goff has filed 22 insider reports with the SEC since March 2021, as chief Executive Officer and director at Agios Pharmaceuticals, Inc. (AGIO), director at Intellia Therapeutics, Inc. (NTLA) and officer at Alexion Pharmaceuticals, Inc. (ALXN). In the last 12 months Brian Goff sold $1.69M of stock on the open market. The latest filing, on June 23, 2026, reports grant or award and exercise or conversion of a derivative at Agios Pharmaceuticals, Inc. (AGIO).
- Filings
- 22
- Companies
- 3
- Bought on market
- None
- Sold on market
- $5.41M
Companies where Brian Goff is an insider
| Company | Role | Shares held | Bought | Sold | Avg buy | Price now | Last filing |
|---|---|---|---|---|---|---|---|
| Chief Executive Officer, Director | 184,508 | $5.41M | $28.76 | Jun 23, 2026 | |||
| Directorsince June 2024 | 32,609 | $9.52 | Jun 10, 2026 | ||||
| Officer | 0 | Jul 23, 2021 |
Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record.
Every filing
- Jun 18, 2026AGIOSEC Form 4 filed by Chief Executive Officer Goff BrianForm 4Grant or awardExercise or conversion of a derivative
- Jun 9, 2026NTLADirector Goff Brian was granted 9,200 shares, increasing direct ownership by 39% to 32,609 unitsForm 4Grant or award
- Apr 2, 2026-$662KAGIOSEC Form 4 filed by Goff BrianForm 4Exercise or conversion of a derivativeOpen-market sale10b5-1 plan
- Mar 2, 2026-$523KAGIOChief Executive Officer Goff Brian converted options into 39,500 shares and sold $522,873 worth of shares (18,055 units at $28.96), increasing direct ownership by 15% to 164,548 unitsForm 4Grant or awardExercise or conversion of a derivativeOpen-market sale10b5-1 plan
- Dec 30, 2025-$507KAGIOChief Executive Officer Goff Brian converted options into 38,278 shares and sold $506,664 worth of shares (18,703 units at $27.09), increasing direct ownership by 16% to 143,103 unitsForm 4Exercise or conversion of a derivativeOpen-market sale10b5-1 plan
- Aug 8, 2025-$406KAGIOChief Executive Officer Goff Brian converted options into 22,691 shares and sold $406,487 worth of shares (11,085 units at $36.67), increasing direct ownership by 10% to 123,528 unitsForm 4Exercise or conversion of a derivativeOpen-market sale10b5-1 plan
- Jun 24, 2025-$627KAGIOChief Executive Officer Goff Brian converted options into 38,277 shares and sold $627,198 worth of shares (18,700 units at $33.54), increasing direct ownership by 21% to 111,922 unitsForm 4Exercise or conversion of a derivativeOpen-market sale10b5-1 plan
- Jun 11, 2025NTLADirector Goff Brian was granted 8,000 shares, increasing direct ownership by 52% to 23,409 unitsForm 4Grant or award
- Mar 3, 2025-$460KAGIOChief Executive Officer Goff Brian converted options into 26,500 shares and sold $460,136 worth of shares (12,947 units at $35.54), increasing direct ownership by 17% to 92,345 unitsForm 4Grant or awardExercise or conversion of a derivativeOpen-market sale10b5-1 plan
- Aug 8, 2024-$474KAGIOChief Executive Officer Goff Brian converted options into 22,691 shares and sold $474,140 worth of shares (11,091 units at $42.75), increasing direct ownership by 17% to 78,792 unitsForm 4Exercise or conversion of a derivativeOpen-market sale10b5-1 plan
- Jun 13, 2024NTLABrian Goff became an insiderForm 3New insider
- Jun 13, 2024NTLADirector Goff Brian was granted 15,409 sharesForm 4Grant or award
- Jun 5, 2024-$592KAGIOGoff Brian converted options into 25,527 shares and sold $591,697 worth of shares (12,115 units at $48.84), increasing direct ownership by 25% to 67,192 unitsForm 4Exercise or conversion of a derivativeOpen-market sale10b5-1 plan
- Mar 5, 2024-$135KAGIOGoff Brian converted options into 8,500 shares and sold $135,361 worth of shares (4,156 units at $32.57), increasing direct ownership by 9% to 53,780 unitsForm 4Grant or awardExercise or conversion of a derivativeOpen-market sale10b5-1 plan
- Jan 24, 2024-$165KAGIOGoff Brian converted options into 17,018 shares and sold $165,221 worth of shares (7,635 units at $21.64), increasing direct ownership by 23% to 49,436 unitsForm 4Exercise or conversion of a derivativeOpen-market sale10b5-1 plan
- Jan 9, 2024-$277KAGIOGoff Brian converted options into 25,527 shares and sold $277,397 worth of shares (12,066 units at $22.99), increasing direct ownership by 51% to 40,053 unitsForm 4Exercise or conversion of a derivativeOpen-market sale10b5-1 plan
- Aug 8, 2023-$259KAGIOSEC Form 4: Goff Brian converted options into 22,691 shares and sold $259,335 worth of shares (10,178 units at $25.48), increasing direct ownership by 89% to 26,592 unitsForm 4Exercise or conversion of a derivativeOpen-market sale
- Jun 30, 2023-$325KAGIOSEC Form 4 filed by Goff BrianForm 4Exercise or conversion of a derivativeOpen-market sale
- Jul 21, 2021ALXNSEC Form 4: Goff Brian returned 150,832 units of Common Stock to the company, closing all direct ownership in the companyForm 4Sale back to the company
- Jul 14, 2021ALXNSEC Form 4: Goff Brian was granted 60,144 units of Common Stock, increasing direct ownership by 66% to 150,832 unitsForm 4Grant or award
- Jun 8, 2021ALXNSEC Form 4: Goff Brian covered exercise/tax liability with 1,086 units of Common Stock, decreasing direct ownership by 1% to 90,688 units (withholding tax)Form 4Shares withheld for taxes or exercise price
- Feb 28, 2021ALXNSEC Form 4: Brian Goff was granted 24,473 units of Common Stock, increasing ownership by 36% to 91,774 unitsForm 4Grant or award
Compare Brian Goff with
- Brian Goff vs John M Leonard1 shared
- Brian Goff vs Sarah Gheuens1 shared
- Brian Goff vs Edward J Dulac III1 shared
- Brian Goff vs Jay T. Backstrom1 shared
- Brian Goff vs Michael P Dube1 shared
- Brian Goff vs Rahul D. Ballal1 shared
Other insiders at the same companies
- John M LeonardNTLA
- Sarah GheuensAGIO
- Edward J Dulac IIINTLA
- Jay T. BackstromAGIO
- Michael P DubeNTLA
- Rahul D. BallalAGIO
- Jeffrey D CapelloAGIO
- Kaye I Foster-CheekAGIO
- Jacqualyn A FouseAGIO
- Maykin HoAGIO
- Adams Catherine OwenAGIO
- David ScaddenAGIO
- Cynthia SmithAGIO
- Krishnan ViswanadhanAGIO
- James William BurnsAGIO
- Cecilia JonesAGIO
Questions about Brian Goff
- What is Brian Goff's role at Agios Pharmaceuticals, Inc.?
- Brian Goff reports to the SEC as chief Executive Officer and director at Agios Pharmaceuticals, Inc. (AGIO), according to the latest filing on June 23, 2026. Brian Goff has also filed as director at Intellia Therapeutics, Inc. (NTLA) and officer at Alexion Pharmaceuticals, Inc. (ALXN).
- How many shares does Brian Goff own?
- After the latest filing that states it, Brian Goff directly owned 184,508 shares of Agios Pharmaceuticals, Inc. (AGIO) and 32,609 shares of Intellia Therapeutics, Inc. (NTLA). Shares held through trusts, funds or family members are reported separately and are not counted here.
- Has Brian Goff bought or sold stock recently?
- The most recent open-market sale was on April 2, 2026: sold 19,068 shares of Agios Pharmaceuticals, Inc. (AGIO) for $662K at an average of $34.71.
- How do I get alerts when Brian Goff files?
- Follow Brian Goff on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.
From SEC Forms 3, 4, 5 and 144 filed by Brian Goff (SEC CIK 0001546216). Totals count each trade once, skipping amendments whose original is on file, from Mar 2, 2021 on. View on SEC EDGAR · Get this as JSON